KD Logo

President and CEO Polymeropoulos Mihael Hristos sale 24,288 shares of Vanda Pharmaceuticals Inc [VNDA]

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Vanda Pharmaceuticals Inc shares valued at $100,273 were sold by Polymeropoulos Mihael Hristos on Mar 05 ’24. At $4.13 per share, Polymeropoulos Mihael Hristos sold 24,288 shares. The insider’s holdings dropped to 1,871,730 shares worth approximately $9.98 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, Wijkstrom Joakim sold 9,229 shares, netting a total of over 38,830 in proceeds. Following the sale of shares at $4.21 each, the insider now holds 129,789 shares.

Before that, Moran Kevin Patrick had sold 8,902 shares from its account. In a trade valued at $37,411, the SVP, CFO & Treasurer traded Vanda Pharmaceuticals Inc shares for $4.20 each. Upon closing the transaction, the insider’s holdings decreased to 8,902 shares, worth approximately $1.23 million.

As published in a research note from Jefferies on February 25, 2022, Vanda Pharmaceuticals Inc [VNDA] has been rated down from a Buy to a Hold and the price target has been revised to $12 from $24. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid May. As of January 14, 2021, Citigroup has decreased its “Buy” rating to a “Neutral” for VNDA. Earlier on October 29, 2020, Citigroup upgraded its rating. Their new recommendation was “a Buy” for VNDA stock which previously was a “a Neutral”.

Analyzing VNDA Stock Performance

During the last five days, there has been a drop of approximately -10.87%. Over the course of the year, Vanda Pharmaceuticals Inc shares have jumped approximately 26.30%. Shares of the company reached a 52-week high of $6.75 on 06/13/24 and a 52-week low of $3.46 on 02/06/24. A 50-day SMA is recorded $5.38, while a 200-day SMA reached $4.42. Nevertheless, trading volume fell to 0.63 million shares from 1.32 million shares the previous day.

Support And Resistance Levels for Vanda Pharmaceuticals Inc (VNDA)

According to the 24-hour chart, there is a support level at 5.27, which, if violated, would cause prices to drop to 5.19. In the upper region, resistance lies at 5.44. The next price resistance is at 5.53. RSI (Relative Strength Index) is 42.92 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.55, which suggests the price will decrease in the coming days. Percent R is at 90.26%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Most Popular